Business Context and Reporting Period
This Form 8-K, dated November 11, 2025, reports material events for Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.). Effective November 12, 2025, the Company changed its name and ticker symbol from "LPTX" to "CYPH." The filing details a strategic pivot to a digital asset treasury strategy, significant executive appointments, and substantial equity grants.
Key Financial Metrics and Transactions
- Digital Asset Acquisition: The Company utilized $50 million in proceeds from a prior private placement to purchase 203,775 Zcash (ZEC) tokens at a weighted average cost of $245.37 per token.
- Equity Grants (Consulting): Granted 2,411,700 RSUs to CoinXit Ltd. (First RSUs) and agreed to an additional 3,036,457 RSUs (Second RSUs) subject to stockholder approval and plan amendments.
- Executive Compensation: Appointed William McEvoy as Chief Investment Officer with a base salary of $250,000, a 40% target bonus, and an award of 5,616,906 RSUs (subject to conditions).
- General Equity Grants: Approved an aggregate of 3,241,687 RSUs for directors and employees. Director RSUs vested immediately; Employee RSUs vest over 36 months.
- Financial Results: The filing references a press release for Q3 2025 results but does not contain specific revenue, profit, or cash flow figures within the text provided.
Material Changes Versus Prior Period
- Corporate Identity: Transitioned from a biotechnology focus (Leap Therapeutics) to a digital asset treasury strategy (Cypherpunk Technologies).
- Leadership: Khing Oei appointed as non-executive Chairman and Class II Director; William McEvoy appointed as Class III Director and Chief Investment Officer. Christopher Mirabelli stepped down as Chairman but remains on the Board.
- Capital Structure: Significant dilution potential via the issuance of over 14 million RSUs in this filing alone, contingent on stockholder approvals for certain grants.
- Operations: Formed a new wholly-owned subsidiary, "Leap Therapeutics, Inc.," to house ongoing R&D activities, separating them from the new treasury strategy.
Guidance, Outlook, and Risks
- Strategy: The Company has unveiled a strategy to accumulate Zcash (ZEC) as a treasury asset.
- Conditions Precedent: Several equity awards (Second RSUs to CoinXit and RSUs to Mr. McEvoy) are contingent upon stockholder approval of a reverse stock split, an increase in authorized shares to at least 490,000,000, and the adoption of a new equity plan.
- Investor Designee Rights: Pursuant to a Lead Investor Agreement with Winklevoss Treasury Investments, LLC, the Lead Investor retains the right to designate two board members (including the Chairman) as long as they hold at least 16.7% of the common stock.
- Financial Data: The filing text does not provide specific revenue, margin, or liquidity metrics for the current period; investors must refer to the referenced Q3 2025 press release (Exhibit 99.2).
Investor Verification Checklist
- Verify the status of the stockholder vote required to approve the reverse stock split and the new equity plan necessary for the Second RSUs and Mr. McEvoy's equity award.
- Confirm the current market price of ZEC relative to the $245.37 weighted average purchase cost to assess immediate unrealized gains or losses.
- Review the full text of the Q3 2025 earnings release (Exhibit 99.2) for specific revenue, cash burn, and liquidity figures not included in this summary.
- Monitor the ticker symbol change from LPTX to CYPH effective November 13, 2025.
- Assess the impact of the new subsidiary structure on the Company's ongoing R&D obligations versus its new treasury mandate.